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Abstract
Background: The World Health Organisation (WHO) defines Russia as one of the 22 highest-burden countries
for tuberculosis (TB). The WHO Directly Observed Treatment Short Course (DOTS) strategy employing a
standardised treatment for 6 months produces the highest cure rates for drug sensitive TB. The Russian TB
service traditionally employed individualised treatment.
The purpose of this study was to implement a DOTS programme in the civilian and prison sectors of Samara
Region of Russia, describe the clinical features and outcomes of recruited patients, determine the proportion of
individuals in the cohorts who were infected with drug resistant TB, the degree to which resistance was attributed
to the Beijing TB strain family and establish risk factors for drug resistance.
Methods: prospective study
Results: 2,099 patients were recruited overall. Treatment outcomes were analysed for patients recruited up to
the third quarter of 2003 (n = 920). 75.3% of patients were successfully treated. Unsuccessful outcomes occurred
in 7.3% of cases; 3.6% of patients died during treatment, with a significantly higher proportion of smear-positive
cases dying compared to smear-negative cases. 14.0% were lost and transferred out. A high proportion of new
cases (948 sequential culture-proven TB cases) had tuberculosis that was resistant to first-line drugs; (24.9%
isoniazid resistant; 20.3% rifampicin resistant; 17.3% multidrug resistant tuberculosis). Molecular epidemiological
analysis demonstrated that half of all isolated strains (50.7%; 375/740) belonged to the Beijing family. Drug
resistance including MDR TB was strongly associated with infection with the Beijing strain (for MDR TB, 35.2%
in Beijing strains versus 9.5% in non-Beijing strains, OR-5.2. Risk factors for multidrug resistant tuberculosis were:
being a prisoner (OR 4.4), having a relapse of tuberculosis (OR 3.5), being infected with a Beijing family TB strain
(OR 6.5) and having an unsuccessful outcome from treatment (OR 5.0).
Conclusion: The implementation of DOTS in Samara, Russia, was feasible and successful. Drug resistant
tuberculosis rates in new cases were high and challenge successful outcomes from a conventional DOTS
programme alone.
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Since the 1990s the World Health Organization Directly
Observed Therapy Short Course (DOTS) management
strategy has become the internationally recommended
approach for tuberculosis (TB) control programmes [1-3].
By the beginning of the new Millennium, 149 countries in
the world had adopted the DOTS strategy to varying
degrees and important measures of DOTS success (case
detection and treatment success) were included in the Mil-
lennium Development Goals framework [4]. In the
former Soviet Union (FSU) only a limited number of
WHO DOTS implementation programmes exist and cur-
rently countries of the FSU report the lowest case detec-
tion rates (22%) with 9% of cases failing treatment and a
death rate of 7% during treatment [4]. WHO has acknowl-
edged that until TB is controlled in Africa and Eastern
Europe, this disease will remain of major world-wide con-
cern; current analysis indicates that it is unlikely that the
Millennium Development Targets for TB will be met in
these regions [4].
Russia is one of 22 TB high-burden countries as defined by
the WHO [5,6]. Russia has a highly-specialised tuberculo-
sis health care system with a large organisationally-vertical
network of specialized institutes, dispensaries, hospitals,
outpatient clinics, sanatoria and rural feldsher points.
Case detection is based largely on the presence of radio-
logical abnormalities on chest X-rays with or without bac-
teriological confirmation detected through a national
policy of compulsory annual fluorographic population
screening [7-9]. In contrast to the WHO recommended
tuberculosis control DOTS strategy, which favour mini-
mising hospital stays, clinical guidelines and health sys-
tem financing incentives, TB patients in Russia experience
frequent and lengthy hospitalisations, and historically
have received individualised treatment regimens with
doses of the main first line drugs and duration of chemo-
therapy varying from internationally accepted standard
treatment regimens. The system also included prolonged
periods of follow-up and repetitive courses of anti-relapse
therapy [10,11].
The rationale for implementing the DOTS strategy in Rus-
sia is to establish cost-effective tuberculosis control by
reducing unnecessary care costs due to lengthy hospitali-
sations, while improving cure rates and reducing the
development of drug resistant TB [3,7,12-14].
In 2002, with assistance from the UK Department for
International Development, a TB control programme that
adhered to internationally accepted norms and standards
was launched by the regional Ministry of Health. We have
reported elsewhere on the considerable body of research
undertaken in Samara that explores the epidemiological
Table 1: WHO treatment categories and outcome definitions [28]
Category Description
I new cases of smear- positive pulmonary tuberculosis and other newly diagnosed seriously ill patients with 
severe forms of tuberculosis (i.e. disseminated tuberculosis, tuberculous meningitis, tuberculosis spondyolitis 
with neurological complications, tuberculosis pericarditis, peritonitis, bilateral or extensive pleurisy, smear-
negative pulmonary tuberculosis with extensive parenchymal involvement, intestinal tuberculosis, genito-urinary 
tuberculosis, etc.)
II relapse and failure patients, those who interrupted treatment, and "other" patients who were previously treated 
for more than 1 month not under a DOTS treatment program
III new cases of smear-negative pulmonary tuberculosis and extra-pulmonary tuberculosis
Outcomes
Cure Patients are considered as cured if his/her smear/culture was positive before the onset of treatment, if they have 
completed a course of anti-tuberculosis chemotherapy and their smear/culture is negative at 5 or more months 
of treatment and at the end of treatment.
Treatment completed* Patients who were smear and culture negative before the onset of treatment and thereafter, and have 
completed a full course of treatment. Patients who were smear and/or culture positive before the onset of 
treatment and have completed a full course of anti-tuberculosis chemotherapy but failed to have the required 
number of negative smears and/or cultures.
Treatment failure A patient who failed to achieve bacteriological conversion within 5 (FIVE) months after the start of treatment, 
or, after previous conversion, becomes sputum smear or culture-positive again. Also a patient who was initially 
smear-negative before starting treatment and became smear-positive after competing the initial phase of 
treatment.
Death Patient who dies for any reason during the course of treatment.
Default (interruption) Patient whose treatment was interrupted for two consecutive months or more.
Transfer out Patient who has been transferred before the completion of his/her treatment to another recording and 
reporting unit and for whom the treatment outcome is not known.
* Treatment success is defined as the sum of patients cured and those who have completed treatment.Page 2 of 10
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and public health challenges being faced by the oblast
[7,9-12], [15-23]
This paper describes the clinical features and outcomes of
patients recruited to a DOTS programme which was
implemented in civilian and prison sectors in Samara
Oblast.
Methods
At the initial stage of implementation of DOTS a standard
protocol was agreed with the Regional Ministry of Health.
This was followed by extensive training of medical doctors
and TB nurses with the involvement of WHO and experts
from Russian Federal TB Institutes. Two project medical
co-ordinators based in Samara were appointed to oversee
implementation which was rolled out in three phases.
Under phase one, initiated in April 2002, patient recruit-
ment commenced at two pilot TB dispensaries in Samara
City and at two TB prison colonies (one, an inpatient
prison facility used for initial therapy, the second an out-
patient facility where continuation of therapy occurred)
that looked after all prisoners with TB in the oblast.
Recruitment was expanded in January 2003, under phase
two, to all TB facilities in Samara city (five dispensaries
and three TB hospitals) and to the neighbouring city
Togliatti. Under phase three, a further rollout occurred in
January 2004 to the rural district of Krasny Yar. We report
results through all three phases and include patients
recruited up to the third quarter of 2004.
Patients were recruited into standard WHO categories
(Table 1). In 2002, initially only new cases were recruited
(category I and III). From April 2003, recruitment was
extended to include relapse cases (category II). Because of
the prevalence of drug resistance and concerns that resist-
ance profiles would be further amplified [23-25] chronic
cases were ineligible for recruitment.
Given implementation of the internationally supported
programme ceased in third quarter 2004, clinical out-
comes presented are until the third quarter of 2003. Out-
comes for patients recruited subsequently were registered
within the newly adopted Russian national system which
continued following this programme [26,27].
Standard TB control treatment outcomes were recorded
(Table 1). Treatment success under the DOTS strategy was
determined by cures and treatment completions and
unsuccessful treatment included patients who failed and
defaulted [28].
A modified feature of the programme was introduced
where patients registered initially under the DOTS cohort
could be transferred to an "individual treatment regi-
men", an approach that reflected the Russian legacy of
individualised approaches to treatment. According to the
prevailing views of Samara phthisiatrists not only patients
who were diagnosed with MDRTB but also some severely
ill patients or those with severe co-morbidities or per-
ceived adverse reactions would be removed from the
DOTS programme and managed within the regional TB
programme using an individualised approach in line
withy earlier Russian traditions. Cases, following recruit-
ment, which were subsequently determined to have MDR
TB, were transferred out to an individually-tailored
MDRTB drug regimen. A further feature of the modifica-
tion of the DOTS programme was the continuation of the
intensive phase of treatment beyond two months (for one
more month) despite patients becoming smear-negative
in the end of the second month of therapy intensive
phase. This was done, in accordance with Russian tradi-
tions, where extensive radiological changes were present.
Standard technical approaches to documentation and
diagnostic/treatment protocols were employed[28]. Spu-
tum collection was performed at recommended intervals.
During the intensive phase of therapy ethambutol was
administered instead of streptomycin because a previous
drug resistance survey had documented very high rates of
primary resistance to streptomycin [9,23].
For all patients smear microscopy and culture was per-
formed at recommended intervals. Smear microscopy and
culture were performed using standard Ziehl-Neilsen
microscopy and culture on Lowenstein-Jensen media. All
positive isolates were tested for drug susceptibility to iso-
niazid, rifampicin, ethambutol and streptomycin. Qual-
ity-assured drug susceptibility testing (DST) was
performed at three civil and one prison site using an abso-
lute concentration method on Lowenstein-Jensen media.
DST was assured by a period of training by staff from the
WHO Supranational Reference Laboratory (SRL) in Lon-
don (Health Protection Agency MRU) and in Samara. A
blinded analysis of a test panel of TB cultures was per-
formed. A proportion (10%) were retested by the SRL in
London.
DNA was extracted and Beijing family strains were ana-
lysed in London and Samara by detection of the IS6110
insertions in the dnaA-dnaN intergenic region on a pro-
portion of sequential isolates (n = 740).
Direct supervision of treatment adherence was completed
by TB nurses at TB hospitals and dispensaries with out-
patients receiving treatment daily or three times weekly.
Upon release, ex-prisoners completed their treatment
upon transfer of their care to the civilian service.Page 3 of 10
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ticipating DOTS sites to support implementation, ensure
recruitment was maintained, and review documentation
and adherence to the protocol. Over-arching project man-
agement group meetings which included all clinical stake-
holders and the project directors from each DOTS site
occurred on a monthly basis.
Socially disadvantaged patients were identified by a
responsible physician at each dispensary and offered addi-
tional support to encourage treatment adherence with
weekly food packages at a cost of 100 Russian Roubles (3
Euros) per person per week.
Data were entered and stored into a password protected
database. The statistical analysis was performed using
Excel and SPSS 12. Proportions with 95% confidence
intervals (CI), relative risks (RR), odds ratios (OR), and χ2
test are used for comparison of categorical variables.
The study was approved by the Samara Regional Ethics
Committee.
Results
2,099 patients were recruited from 1st April 2002 to 30th
September 2004, including 1,971 individuals with pul-
monary tuberculosis (93.9%) and 128 patients with
extrapulmonary disease (6.1%); 1,684 of recruits were
men (80.2%) and 415 (19.8%) women. 640 patients were
recruited in the prison sector and 1459 were civilian TB
patients.
One third (33.1%; 694/2,099) of recruited patients were
WHO category I and 24.3% (162/694) of these were
smear-negative cases with extensive parenchymal involve-
ment; 58.8% (1,234/2,099) of cases were WHO category
III patients. Recruitment into WHO category II was lim-
ited to relapse cases only and 171 patients (8.1%) were
recruited.
The mean age of patients was 38.5 years (95%CI 37.9–
39.1 years; range: 16–90 years) with prisoners being sig-
nificantly younger than civilians (mean age 30.9 years;
95%CI 30.2–31.6 years versus mean age 41.9 years;
95%CI 41.1–42.7 years). Female patients were older than
male patients (mean age of men was 38.0 (95%CI 37.4–
38.6) years and mean age of women with TB was 40.4
(95%CI 38.8–42.0) years).
Details of bacteriologically (smear and/or culture) con-
firmed cases are shown in Table 2. Table 3 shows differ-
ences between the infectious status of civilian and prison
populations with TB where civilians were more likely to
have infectious disease whether determined by smear sta-
tus or culture status. Overall the rate of laboratory diag-
nosed TB cases was slightly higher in civilian patients than
prisoners.
Cultures from 948 sequentially new and 94 relapse cases
were isolated and tested for susceptibility to first-line
drugs. Of the new cases, 24.9% (236/948) new cases had
isolates resistant to isoniazid, 20.3% (192/948) new cases
had isolates resistance to rifampicin, and 17.3% (164/
948) had MDRTB (vs 34.0% (32/94) of relapse cases
being MDR (OR-2.5; 95%CI 1.6–3.9). Table 3 and Figure
1 show the differences between civilian and prison
patients.
Table 2: Proportion of bacteriologically confirmed new and relapse pulmonary cases (II quarter 2002 – III quarter 2004)
Microscopy Culture
Total No of 
cases
Smear positive Smear negative- Total No of 
cases
Culture positive Culture 
negative
New cases
Civil 1227 462 (37.7%) 765 (62.3%) 1341 764 (57.0%) 577 (43.0%)
Prison 586 70 (11.9%) 516 (88.1%) 587 184 (31.3%) 403 (68.7%)
Total 1813 532 (29.3%) 1281(70.7%) 1928 948 (49.2%) 980 (50.8%)
Relapses
Civil 101 39 (38.6%) 62 (61.4%) 118 76 (64.4%) 42 (35.6%)
Prison 51 5 (9.8%) 46 (90.2%) 53 18 (34.0%) 35 (66.0%)
Total 152 44 (28.9%) 108 (71.1%) 171 94 (55.0%) 77 (45.0%)
Total sample (new and relapse cases)
Civil 1328 501 (37.7%) 827 (62.3%) 1459 840 (57.6%) 619 (42.4%)
Prison 637 75 (11.8%) 562 (88.2%) 640 202 (31.6%) 438 (68.4%)
Total 1965 576 (29.3%) 1389 (70.7%) 2099 1042 (49.6%) 1057 (50.4%)
*a proportion of patients could not expectorate a sputum sample of a quality that would be suitable for culturingPage 4 of 10
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half of all isolated strains (50.7%; 375/740) belonged to
the Beijing family. Of note, seven isolates (0.9%) were
mixed strains. The prevalence of the Beijing strain (60.9%;
117/192) among prisoners was significantly higher (OR-
1.7; 95% CI 1.2–2.4) than in civilians (47.1%; 258/548)
confirming earlier research findings in a drug resistance
survey in the same region in the preceding year [19].
For 709 isolates data on both drug resistance and strain
type were available (31 isolates were non-viable or were
contaminated and DST could not be performed). Drug
resistance including MDR TB was strongly associated with
being infected with the Beijing strain (for MDR TB 35.2%
in Beijing strains versus 9.5% in non-Beijing strains, OR-
5.2 (3.4–7.9) (Table 5) confirming earlier research in a
different population of patients treated under the Russian
system in the same region[19].
Table 3: Difference in infectious status between civilians and prisoners
Civil (n positive/total 
tested, %)
Prison (n positive/total 
tested, %)
OR (95%CI) RR (95%CI)
New cases
Smear+ * 462/1227 (37.7%) 70/586 (11.9%) 4.5 (3.4–5.9) 3.2 (2.5–4.0)
Culture+ * 764/1341 (57.0%) 184/587 (31.3%) 2.9 (2.4–3.6) 1. 8 (1.6–2.1)
Relapses
Smear+ * 39/101 (38.6%) 5/51 (9.8%) 5.8 (2.1–15.8) 3.9 (1.7–9.4)
Culture+ * 76/118 (64.4%) 18/53 (34.0%) 3.5 (1.8–7.0) 1.9 (1.3–2.8)
Total sample (new and relapse cases)
Smear+ * 501/1328 (37.7%) 75/637 (11.8%) 4.5 (3.5–5.9) 3.2 (2.6–4.0)
Culture+ * 840/1459 (57.6%) 202/640 (31.6%) 2.9 (2.4–3.6) 1.8 (1.6–2.1)
* statistically significant at p < 0.05
Rates of first-line drug resistance among civil and prison patientsFigure 1
Rates of first-line drug resistance among civil and prison patients.Page 5 of 10
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4.4; 95%CI 2.7–7.1), having a relapse of TB (OR-3.5;
95%CI 1.7–7.1), being infected with the Beijing family
strains (OR-6.5; 95%CI 4.0–10.5) and having unsuccess-
ful outcome of treatment (OR-5.0; 95%CI 1.1–22.7) were
risk factors for MDR TB.
During the course of treatment the majority (97.7%; 284/
290) of smear-positive new cases converted by the end of
the intensive phase of treatment.
Treatment outcomes among new cases confirmed by cul-
ture are shown in Table 6. Because recruitment of relapses
was initiated at a later stage, the number of these is small.
Overall 85.4% (786/920) of newly diagnosed and
recruited patients were treated according to the WHO pro-
tocol. Nearly fifteen percent (134/920) of patients were
transferred out of the DOTS clinical protocol and this
included patients transferred to individual regimens
because MDRTB (17.3% of all new cases were MDR and
34.0% of all relapse cases) or extensive radiological
abnormalities, adverse drug reactions, or co-morbidities).
MDR TB patients were removed from the programme
according to DOTS project criteria and further treated
with tailored schemes using second-line drugs. More
smear positive patients were transferred out than smear-
negative cases (22.4% versus 11.6%; OR-2.2; 95%CI 1.5–
3.2). In total 75.3% (592/786) of patients were success-
fully treated and in 7.3% (57/786) treatment failed or
patients defaulted. The odds of failing treatment or
defaulting were higher in smear positive patients (OR –
10.6; 95% CI 3.4–32.8).
There was no statistically significant difference in treat-
ment outcomes between male and female patients.
The rates of unsuccessful treatment was higher among
civilians compared to prisoners (OR-4.5; 95%CI 2.1–
10.0)
Twenty-eight patients (3.6 %; 28/786) died during the
course of treatment with a significantly higher proportion
Table 4: Difference in resistance rates between civil and prison patients
New cases Prison and civilian 
(N-948)
Prison (N-184) Civil (N-764) OR (95%CI) RR (95%CI)
Inh* 236 (24.9%) 90 (48.9%) 146 (19.1%) 3.6 (2.5–5.1) 2.6 (2.0–3.2)
Rif* 192 (20.3%) 71 (38.6%) 121 (15.8%) 3.0 (2.1–4.2) 2.4 (1.9–3.1)
MDR TB* 164 (17.3%) 69 (37.5%) 95 (12.4%) 3.8 (2.6–5.5) 3.0 (2.3–3.9)
S* 215 (22.7%) 91 (49.5%) 124 (16.2%) 4.5 (3.2–6.4) 3.0 (2.5–3.8)
E* 115 (12.1%) 44 (23.9%) 71 (9.3%) 2.7 (1.8–4.2) 2.6 (1.8–3.6)
Relapses Prison and civilian 
(N- 94)
Prison (N-18) Civil (N-76) OR (95%CI) RR (95%CI)
Inh* 38 (40.4%) 16 (88.9%) 22 (28.9%) 16.4 (3.5–77.6) 3.1 (2.1–4.5)
Rif* 38 (40.4%) 15 (83.3%) 23 (30.3%) 10.0 (2.5–36.5) 2.8 (1.9–4.10
MDR TB* 32 (34.0%) 15 (83.3%) 17 (22.4%) 14.7 (3.8–57.1) 3.7 (2.3–5.9)
S* 34 (36.2%) 16 (88.9%) 18 (23.7%) 21.8 (4.5–104.3) 3.8 (2.4–5.8)
E* 23 (24.5%) 12 (66.7%) 11 (14.5%) 10.2 (3.1–32.9) 4.6 (2.4–8.7)
*statistically significant at p < 0.05
Table 5: Comparison of first-line resistance levels in Beijing compared to non-Beijing strains (n = 709^)
Drug Beijing strain (n = 361) Non-Beijing strain (n = 348) OR (95%CI) RR (95%CI) RD (95%CI)
N resistant % resistant 
(95%CI)
N resistant % resistant 
(95%CI)
Isoniazid* 170 47.1 (48.0–52.3) 53 15.2 (11.7–19.3) 5.0 (3.5–7.1) 3.1 (2.4–4.1) 31.9 (25.2–38.5)
Rifampicin* 140 38.8 (33.9–43.9) 41 11.8 (8.7–15.5) 4.7 (3.2–7.0) 3.3 (2.4–4.5) 27.0 (20.7–33.3)
MDR TB* 127 35.2 (30.4–40.2) 33 9.5 (6.7–12.9) 5.2 (3.4–7.9) 3.7 (2.6–5.3) 25.7 (19.6–31.8)
Streptomycin* 144 39.9 (34.9–45.0) 45 12.9 (9.7–16.8) 4.5 (3.1–6.5) 3.1 (2.3–4.2) 27.0 (20.5–33.4)
Ethambutol* 89 24.7 (20.4–29.3) 26 7.5 (5.0–10.6) 4.1 (2.5–6.5) 3.3 (2.2–5.0) 17.2 (11.7–22.)
* statistically significant difference at p < 0.001
^ both epidemiological and drug resistance results were available for 709/1042 (68.0%) cultures; 31 cultures were non viable or contaminated; 
cultures were drawn from all dispensaries and prison facilities in Samara City.Page 6 of 10
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Table 6: Cohort outcomes for new cases confirmed by culture
Total 
registered
Total 
remaining 
in cohorts** 
n, %
Excluded 
from 
cohorts* n, 
%
Cured n, % Treatment 
completed 
n, %
Successful 
treatment 
n,% rows e+f
Failure n, % Default n, % Unsuccessfu
l treatment 
n, % rows h+i
Died n, % Lost and 
transferred 
out n, %
a b c d e f g h i j k l
Civil 569 467 (82.1) 102(17.9) 106 (22.7) 263(56.3) 369(79.0%) 12(2.6) 36 (7.7) 48(10.3) 28 (6.0) 22 (4.7)
Smear+ 207 161 (77.8) 46 (22.2) 106 (65.8) 0 (0.0) 106 (65.8%) 11 (6.8) 16 (9.9) 27 (16.8) 22 (13.7) 6 (3.7)
Smear- 362 306 (84.5) 56 (15.5) 0 (0.0) 263 (85.9) 263 (85.9%) 1 (0.3) 20 (6.5) 21 (6.9) 6 (2.0) 16 (5.2)
Culture+ --- 266 --- 95 (35.7) 103 (38.7) 198 (74.4%) 11 (4.1) 23 (8.6) 34 (12.8) 25 (9.4) 9 (3.4)
Culture- --- 201 --- 11 (5.5) 160 (79.6) 171(85.1%) 1 (0.5) 13 (6.5) 14 (7.0) 3 (1.5) 13 (6.5)
Prison 351 319 (90.9) 32 (9.1) 5 (1.6) 218(68.3) 223(69.9%) 5 (1.6) 3 (0.9) 8 (2.5) 0 (0.0) 88(27.6)
Smear+ 43 33 (76.7) 10 (23.3) 5 (15.2) 11 (33.3) 16 (48.5%) 2 (6.1) 0 (0.0) 2 (6.1) 0 (0.0) 15 (45.5)
Smear- 308 286 (92.9) 22 (7.1) 0 (0.0) 207 (72.4) 207 (72.4%) 3 (1.0) 3 (1.0) 6 (2.1) 0 (0.0) 73 (25.5)
Culture+ --- 74 --- 4 (5.4) 44 (59.5) 48 (64.9%) 3 (4.1) 0 (0.0) 3 (4.1) 0 (0.0) 23 (31.1)
Culture- --- 245 --- 1 (0.4) 174 (71.0) 175 (71.4%) 2 (0.8) 3 (1.2) 5 (2.0) 0 (0.0) 65 (26.5)
Total 920 786 (85.4) 134(14.6) 111 (14.1) 481(61.2) 592(75.3%) 17(2.2) 40 (5.1) 57 (7.3) 28 (3.6) 110(14.0)
Smear+ 250 194 (77.6) 56 (22.4) 111 (57.2) 11 (5.7) 122 (62.9%) 13(6.7) 16 (8.2) 29 (14.9) 22 (11.3) 21(10.8)
Smear- 670 592 (88.4) 78 (11.6) 0 (0.0) 470 (79.4) 470 (79.4%) 4 (0.7) 23 (3.9) 27 (4.6) 6 (1.0) 89(15.0)
Culture+ --- 340 --- 99 (29.1) 147 (43.2) 246 (72.4%) 14 (4.1) 23 (6.8) 37(10.9) 25 (7.4) 32 (9.4)
Culture- --- 446 --- 12 (2.7) 334 (74.9) 346 (77.6%) 3 (0.7) 16 (3.6) 19 (4.3) 3 (0.7) 78 (17.5)
*a proportion of patients were excluded from cohort (transferred to a different regimen due to MDR TB, extensive radiological abnormalities, drug adverse reactions, severe accompanying 
pathology)
** N of patients remained in the cohort (column "total") is taken as a denominator
Respiratory Research 2006, 7:44 http://respiratory-research.com/content/7/1/44(11.3%) of smear-positive cases dying versus smear-nega-
tive (OR -12.5; 95%CI 5.0–31.3).
Discussion and conclusion
The WHO have argued that the introduction of DOTS
cohort treatment strategies improves case detection and
treatment and leads to a reduction in TB prevalence and
death rates by cutting the duration of illness and case
fatality.
Two examples from middle and high incidence countries
(Peru and China) support this view. In Peru, the incidence
rate of pulmonary TB has decreased annually by 6% after
the nationwide implementation of DOTS[29]. In 13 prov-
inces of China that implemented DOTS, the prevalence
rate of culture-positive TB was cut by 30% between 1990
and 2000 [30]
The introduction of DOTS resulted in profound changes
to the delivery of clinical care within the Samara TB Serv-
ice. Although a direct observation component had,
broadly. been present within the old system through
lengthy hospitalisation periods, the strict adherence of
physicians to standard regimens, the emphasis on labora-
tory diagnosis, and a robust system of recording and
reporting of cohorts were new [7].
Similarly fewer than 70% of patients with TB were cured
or completed treatment in Samara compared to 75.3% in
the cohort groups. This is in keeping with the cure rates
reported for DOTS programmes internationally (Table 7)
and the global treatment success rate under DOTS has
been high since the first observed cohort in 1994
(77%)[4].
The relatively high failure rates noted elsewhere in Eastern
Europe, (9% of cases failed treatment and 7% died during
treatment) are believed to be associated with high rates of
multidrug resistance (which in itself is an indicator of a
programme with low cure rates previously). In Samara,
prior to the introduction of the DOTS cohort strategy we
established that drug resistance was high in both new
(approx 20%) and chronic cases in Samara [9,17,23].
Dye et al [4] further established that the prevalence will
decrease sooner if case detection by DOTS programs (and
hence the quality of treatment) can be improved more
quickly, thus reducing the burden of illness during this
period in future years. The DOTS programmes emphasise
the importance of bacteriological confirmation. [7]Prior
to the establishment of the cohort, there were more than
1.5 million flurographic examinations of the general pop-
ulation for early diagnosis of TB reflecting the national
policy of fluorography screening of the population for TB
for early diagnosis. We have reported on the subjective
nature of radiological examination elsewhere [31] and
emphasised the need for bacteriological confirmation of
the diagnosis in line with international standards.
Previously, less than one-third (30.1%) of cases were bac-
teriologically confirmed (Coker et al, 2003 IUATLD) com-
pared to the DOTS cohort where 49.6% of all cases (and
57.6% in civilian cases) were bacteriologically confirmed.
[10,11]Overall the proportion of cases which had a bacte-
riological confirmation of the diagnosis was similar to
rates reported from other regions of Russia [4];.
[31]Although the laboratory component of the TB service
in Samara Oblast has been extensively upgraded and
improved with prison and civil laboratory services work-
ing to these improved standards, maintenance and further
quality improvement remains a priority. Without appro-
priate laboratory support, over-diagnosis of tuberculosis
remains a possibility, resulting in unnecessary treatment
and side-effects without benefit, and compounding serv-
ice inefficiencies [13].
Relatively low default rates occurred with implementation
of DOTS in Samara. This may be, in part, attributable to a
programme of externally financed social support. This
component was discontinued after external funding
ceased, and it remains to be seen whether adherence rates
will suffer. Of note, substance abuse, alcoholism, poverty
Table 7: Comparison of Samara DOTS cohort with overall treatment success and outcome for global DOTS cohorts in 2002
% Died Failed Defaulted Treatment success
Samara, Russia 3.6 2.2 5.1 75.3
Eastern Europe 6.7 8.8 6.4 74.9
Central europe 5.0 3.5 6.0 79.7
East Mediterranean 3.2 1.4 7.8 83.5
Established markets 9.7 2.4 2.6 76.5
Latin America 4.3 1.2 6.0 83.4
Southeast asia 3.9 2.5 6.4 85.1
Western Pacific 2.2 0.9 2.2 89.1
Established markets include member states of the EU, North America, Australia, New Zealand and Japan.Page 8 of 10
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TB in Samara Oblast, co-factors likely to influence treat-
ment adherence [22]. The sustainable success of DOTS in
Russia is likely to be dependent on how care and support
for these social and behavioural factors are integrated into
TB care systems.
Effective responses in support of TB control demand polit-
ical commitment and investment from local and federal
budgets into non-medical support to patients and their
families. However, few integrated social support systems
for tuberculosis patients currently exist, and current laws
and regulations have the potential to ensure that health
and social care budgets remain disconnected from each
other and from need [32,33]. Consequently, to compen-
sate for inadequate social support systems for tuberculosis
patients, providers use sophisticated practices to ensure
lengthy admissions in the winter months – a response to
social rather than medical need [32,33]. Whilst the two
recent decrees on TB control issued in 2003 (#109 and
#50) [26,27] support convergence of Russian TB control
practices with WHO's DOTS strategy (with some specific
differences reflecting Russia's clinical legacy), the sustain-
ability of reforms needed to ensure cost-effective imple-
mentation such that DOTS implementation is allied to
structural reform remains uncertain.
The rate of successful treatment (75.3% overall and 79.0%
in civil sector) though below the 85% WHO target, was
higher than reported from other several DOTS pilot
regions in the former Soviet Union (68.1% according to
the meta-analysis performed by Faustini et al, 2005 [25]).
The zero mortality among prisoners may be misleading:
several patients died after data censoring. Furthermore,
policy that very severely ill patients are released from
prison for treatment in the civilian sector means that
deaths of these ex-prisoners are recorded as civilian
deaths.
The high prevalence of drug resistance and the frequency
of the Beijing strain family (previously shown to be asso-
ciated with drug resistance) [19] remains a major clinical
and public health challenge. Extremely high rates of drug
resistance among prisoners despite significantly lower
default rates in prison likely reflects on-going transmis-
sion of resistant strains. Rapid isolation of MDR TB cases,
good co-ordination between the prison and civilian TB
services and enhancement of infection control and treat-
ment are needed to prevent further nosocomial and insti-
tutional spread of MDR TB and would increase the success
of the current TB programme. This issue is likely to
become considerably more of a problem as the emergent
epidemic of HIV in Samara matures
Although the DOTS strategy does not include specific
therapy for multi-drug resistant cases its effective imple-
mentation reduces the occurrence and further transmis-
sion of resistant strains [34]. However, in regions such as
Samara with very high rates of MDR TB it is essential to
ensure the availability of appropriate and timely diagnosis
and treatment of existing cases as well as preventing the
development of new ones. Rapid drug susceptibility tech-
niques, with appropriate treatment to be tailored to cir-
cumstance may be necessary. Cost-effectiveness analysis
of rapid methods in the post-Soviet context is required to
inform investment and policy changes.
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